Protocol of a randomised trial of teriparatide followed by zoledronic acid to reduce fracture risk in adults with osteogenesis imperfecta
Introduction Osteogenesis imperfecta (OI) is a rare genetic disease associated with multiple fractures throughout life. It is often treated with osteoporosis medications but their effectiveness at preventing fractures is unknown. The Treatment of Osteogenesis Imperfecta with Parathyroid Hormone and...
Saved in:
Main Authors: | Jennifer Walsh, Catriona Keerie, Stuart H Ralston, Christopher J Weir, Muhammad K Javaid, WAYNE LAM, Bente L Langdahl, Jannie D Hald, Patricia Osborne |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2023-11-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/13/11/e078164.full |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
HRQoL Evaluation of Pediatric Osteogenesis Imperfecta with Zoledronic Acid Therapy
by: Tri Wahyu Martanto, et al.
Published: (2023-10-01) -
Wish Bone Day: Raising Awareness for Osteogenesis Imperfecta – Global and India
by: Yuvaraja Murugan, et al.
Published: (2023-07-01) -
Pleiotropic effects of a recessive Col1a2 mutation occurring in a mouse model of severe osteogenesis imperfecta.
by: Michelangelo Corcelli, et al.
Published: (2025-01-01) -
Annual Zoledronic Acid for the Treatment of Osteoporosis: A Randomized Controlled Trial
by: Asif Hussain, et al.
Published: (2023-01-01) -
Management of Complex Nonunion of Long Bones by Distraction Osteogenesis Using Monorail Fixator
by: Azad Khan, et al.
Published: (2024-01-01)